跳至主要内容
临床试验/EUCTR2012-002035-29-ES
EUCTR2012-002035-29-ES进行中(未招募)不适用

A Randomized, Double-blind, Placebo-controlled Study to Evaluate theEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)and ABT-333 Co administered with Ribavirin (RBV) in Treatment-Experienced Adults with Genotype 1 Chronic Hepatitis C Virus (HCV)Infection (SAPPHIRE-II)

Abbott GmbH & Co. KG0 个研究点目标入组 400 人开始时间: 2013年5月9日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Males and females 18-70 years old, inclusive
  • - Females must be post-menopausal for more than 2 years or surgically
  • sterile or practicing specific forms of birth control.
  • - Chronic hepatitis C, genotype 1 infection
  • - Failed previous treatment with pegIFN and RBV
  • - No evidence of liver cirrhosis
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 360
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 40

排除标准

  • -Positive screen for drugs or alcohol
  • -Significant sensitivity to any drug
  • -Use of contraindicated medications within 2 weeks of dosing
  • -Abnormal laboratory tests
  • -Positive hepatitis B surface antigen and anti-Human Immunodeficiency Virus antibody

研究者

相似试验

进行中(未招募)
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中(未招募)
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placebo
EUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中(未招募)
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861
EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中(未招募)
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078
EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943
NL-OMON30044Janssen-Cilag82